BIOINVEST BREAKING NEWS – VKTX reported excellent data this morning with VK2735 showing a 22% placebo-adjusted weight loss at 33 weeks without a plateau in their maintenance dosing trial. (…more)
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.